{"id":59398,"date":"2026-03-13T21:30:15","date_gmt":"2026-03-13T13:30:15","guid":{"rendered":"https:\/\/flcube.com\/?p=59398"},"modified":"2026-03-13T21:30:17","modified_gmt":"2026-03-13T13:30:17","slug":"everest-medicines-reports-positive-phase-iia-data-for-vis-101-dual-vegf-a-ang-2-inhibitor-shows-best-in-class-potential-in-wamd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59398","title":{"rendered":"Everest Medicines Reports Positive Phase IIa Data for VIS-101 \u2013 Dual VEGF-A\/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD"},"content":{"rendered":"\n

Everest Medicines<\/strong> (HKG: 1952<\/a>) announced positive topline results<\/strong> from its Phase IIa study of VIS-101<\/strong>, an investigational dual-functional biologic targeting VEGF-A and Ang-2<\/strong> for wet age-related macular degeneration (wAMD)<\/strong>. The data demonstrated rapid onset of action, potent and durable therapeutic response, and favorable safety<\/strong>, validating its potential as a “best-in-class” therapy<\/strong> for long-term durability in retinal vascular diseases.<\/p>\n\n\n\n

Phase IIa Study Results<\/h2>\n\n\n\n
Endpoint<\/th>VIS-101 Performance<\/th>Clinical Significance<\/th><\/tr><\/thead>
Onset of Action<\/strong><\/td>Rapid<\/td>Immediate visual acuity benefits vs. standard of care<\/td><\/tr>
Efficacy<\/strong><\/td>Potent and durable therapeutic response<\/td>Reduced injection frequency potential<\/td><\/tr>
Safety\/Tolerability<\/strong><\/td>Favorable profile<\/td>Supports long-term chronic administration<\/td><\/tr>
Best-in-Class Potential<\/strong><\/td>Validated<\/td>Dual-target mechanism vs. monotherapy alternatives<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Study Design:<\/strong> Phase IIa trial in wAMD patients; data supports expansion to diabetic macular edema (DME) and retinal vein occlusion (RVO)<\/p>\n\n\n\n

Product Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>VIS-101 Specification<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Dual inhibition of VEGF-A<\/strong> (vascular permeability) + Ang-2<\/strong> (vascular stability)<\/td><\/tr>
Format<\/strong><\/td>Novel biologic; investigational ophthalmic injectable<\/td><\/tr>
Differentiation<\/strong><\/td>Addresses both pathological angiogenesis and vascular destabilization vs. anti-VEGF monotherapies<\/td><\/tr>
Target Indications<\/strong><\/td>wAMD (lead), DME, RVO<\/td><\/tr>
Expected Benefit<\/strong><\/td>More enduring therapeutic effect; reduced treatment burden<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Scientific Rationale:<\/strong> Ang-2 inhibition stabilizes vasculature compromised by VEGF-driven neovascularization, potentially extending durability beyond first-generation anti-VEGF agents (ranibizumab, aflibercept).<\/p>\n\n\n\n

Licensing & Geographic Rights<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Visara (subsidiary of NovaBridge Biosciences, NASDAQ: NBP)<\/td><\/tr>
Licensee<\/strong><\/td>Everest Medicines (HKG: 1952)<\/td><\/tr>
Territory<\/strong><\/td>Greater China, Singapore, South Korea, select Southeast Asian countries<\/td><\/tr>
Rights<\/strong><\/td>Exclusive clinical development, manufacturing, commercialization<\/td><\/tr>
Deal Date<\/strong><\/td>October 2025<\/td><\/tr>
Deal Terms<\/strong><\/td>Not disclosed; typical milestone\/royalty structure for Phase II assets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Position<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
wAMD Market Size<\/strong><\/td>Greater China $3+ billion<\/strong> annually; growing elderly population drives incidence<\/td><\/tr>
Standard of Care<\/strong><\/td>Anti-VEGF monotherapies (aflibercept, ranibizumab biosimilars) require monthly\/bimonthly injections<\/td><\/tr>
Durability Gap<\/strong><\/td>~40% of patients lose vision between injections; VIS-101 dual-target approach addresses unmet need for extended dosing intervals<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Faricimab (Roche) first dual Ang-2\/VEGF-A approved; VIS-101 positions as regional alternative with potentially differentiated profile<\/td><\/tr>
Pipeline Synergy<\/strong><\/td>Everest’s ophthalmology portfolio includes other retinal assets; VIS-101 anchors wAMD franchise<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n